Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 12/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226671 | 0.91 | CCR1 (0.45) | CCR1CXCR3 | |
| SCHEMBL3226680 | 0.91 | CCR1 (0.45) | CCR1CXCR3 | |
| SCHEMBL3223618 | 0.90 | CXCR3 (0.39) | CCR1CXCR3 | |
| SCHEMBL3223629 | 0.90 | CXCR3 (0.39) | CCR1CXCR3 | |
| SCHEMBL15096076 | 0.89 | CCR1 (0.46) | CCR1TGFBR1KCNH2 | |
| SCHEMBL15096078 | 0.87 | CCR1 (0.46) | CCR1CXCR3TGFBR1LIMK2KCNH2 | |
| SCHEMBL26188298 | 0.85 | CCR1 (0.45) | CCR1CXCR3KCNH2 | |
| SCHEMBL10063573 | 0.84 | CCR1 (0.54) | CCR1CXCR3 | |
| SCHEMBL3224268 | 0.83 | CCR1 (0.42) | CCR1CXCR3TGFBR1LIMK2KCNH2 | |
| SCHEMBL3225299 | 0.83 | CCR1 (0.42) | CCR1CXCR3TGFBR1LIMK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170290808-A1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CHEMOCENTRYX, INC. | 2017-10-12 | — | — | US | disclosed |
| US-8946240-B2 | 4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines | CHEMOCENTRYX, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130178623-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX, INC. (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290808-A1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CCR1, CCRL2, CCR3 | CCR1 1/4885CXCR3 9/4885TGFBR1 175/4885 |
| US-20130178623-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885CXCR3 11/4885TGFBR1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.